Kronos Bio Inc
NASDAQ:KRON
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.727
1.5
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Kronos Bio Inc
Kronos Bio Inc
Other Long-Term Assets
Kronos Bio Inc
Other Long-Term Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Long-Term Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Kronos Bio Inc
NASDAQ:KRON
|
Other Long-Term Assets
$2.6m
|
CAGR 3-Years
6%
|
CAGR 5-Years
54%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Other Long-Term Assets
$8.3B
|
CAGR 3-Years
20%
|
CAGR 5-Years
44%
|
CAGR 10-Years
26%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Other Long-Term Assets
$7.2B
|
CAGR 3-Years
15%
|
CAGR 5-Years
10%
|
CAGR 10-Years
23%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Other Long-Term Assets
$10.4B
|
CAGR 3-Years
18%
|
CAGR 5-Years
43%
|
CAGR 10-Years
21%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Other Long-Term Assets
$3.2B
|
CAGR 3-Years
49%
|
CAGR 5-Years
17%
|
CAGR 10-Years
95%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Other Long-Term Assets
$4.1B
|
CAGR 3-Years
70%
|
CAGR 5-Years
34%
|
CAGR 10-Years
31%
|
|
Kronos Bio Inc
Glance View
Kronos Bio, Inc. is a clinical-stage biopharmaceutical, engages in the provision of discovery and development of novel cancer therapeutics products. The company is headquartered in San Mateo, California and currently employs 96 full-time employees. The company went IPO on 2020-10-09. The firm is focused on the discovery and development of cancer therapeutics designed to target dysregulated transcription. Its product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks (TRNs) that drive their oncogenic activity. Its lead product candidate, entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase (SYK) inhibitor that is being developed for the treatment of acute myeloid leukemia (AML). Its second product candidate, KB-0742, is generated from its product engine’s small molecule microarray (SMM) platform. KB-0742 is designed to be an orally bioavailable inhibitor of CDK9 with a differentiated selectivity profile. Its KB-0742 is in advanced solid tumors with MYC genomic copy number gain (amplification).
See Also
What is Kronos Bio Inc's Other Long-Term Assets?
Other Long-Term Assets
2.6m
USD
Based on the financial report for Dec 31, 2023, Kronos Bio Inc's Other Long-Term Assets amounts to 2.6m USD.
What is Kronos Bio Inc's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 5Y
54%
Over the last year, the Other Long-Term Assets growth was -19%. The average annual Other Long-Term Assets growth rates for Kronos Bio Inc have been 6% over the past three years , 54% over the past five years .
You don't have any saved screeners yet
